Literature DB >> 12824862

The human chorionic gonadotropin test is more powerful than the gonadotropin-releasing hormone agonist test to discriminate male isolated hypogonadotropic hypogonadism from constitutional delayed puberty.

V Degros1, C Cortet-Rudelli, B Soudan, D Dewailly.   

Abstract

OBJECTIVE: The effectiveness of biological investigations aiming at discriminating isolated hypogonadotropic hypogonadism (IHH) from constitutional delayed puberty (CDP) in male patients is still controversial. We revisited the diagnostic power of the basal serum testosterone level, the Triptorelin test and the human chorionic gonadotropin (hCG) test in a cohort of 33 boys with delayed puberty.
DESIGN: Boys were aged 14.2 to 26.2 Years at referral. A 5-Year-long clinical follow-up after the initial study allowed confirmation of the diagnosis. At the end of the follow-up period, IHH was found in 13 patients while the other 20 had normal spontaneous pubertal development (CDP).
RESULTS: At referral, a basal morning testosterone level >1.7 nmol/l was observed in 55% of patients with CDP exclusively (predictive positive value (PPV)=100%; predictive negative value (PNV)=59%). For CDP, the PPV of the LH peak 3 h after Triptorelin was 100% by setting the upper threshold at 14 IU/l and the PNV was 72%. However, no lower threshold could discriminate IHH from CDP in the remaining patients with an LH peak 3 h after Triptorelin <14 IU/l. In CDP patients, the PPV of the serum testosterone increment after hCG stimulation (deltaT/hCG) was 100% for values >9 nmol/l (PNV=72%). In IHH patients, the PPV of deltaT/hCG was 100% for values <3 nmol/l (PNV=82%). Only 29% of the studied population had a deltaT/hCG between these lower and upper thresholds and therefore could not have been classified initially.
CONCLUSIONS: (i) Dynamic testing for the diagnosis of delayed puberty is useful only when the basal testosterone level is lower than 1.7 nmol/l; (ii) in that case, the hCG test has better discriminating power than the Triptorelin test and appears as the best cost-effective investigation. It prevents useless and expensive investigations in about one-half of CDP patients with a basal morning testosterone level lower than 1.7 nmol/l.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824862     DOI: 10.1530/eje.0.1490023

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Application of hormonal treatment in hypogonadotropic hypogonadism: more than ten years experience.

Authors:  Luo Yang; Si Xiao Zhang; Qiang Dong; Zi Bing Xiong; Xiang Li
Journal:  Int Urol Nephrol       Date:  2011-10-12       Impact factor: 2.370

Review 2.  Male hypogonadism.

Authors:  Andrea M Isidori; Elisa Giannetta; Andrea Lenzi
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

3.  Osteocalcin Levels in Male Idiopathic Hypogonadotropic Hypogonadism: Relationship With the Testosterone Secretion and Metabolic Profiles.

Authors:  Yu-Ying Yang; Si-Chang Zheng; Wen-Cui Wang; Zu-Wei Yang; Chang Shan; Yu-Wen Zhang; Yan Qi; Yu-Hong Chen; Wei-Qiong Gu; Wei-Qing Wang; Hong-Yan Zhao; Jian-Min Liu; Shou-Yue Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-11       Impact factor: 5.555

4.  The Role of Urinary LH and FSH in the Diagnosis of Pubertal Disorders.

Authors:  Manoranjan Tripathy; A K Baliarsinha; A K Choudhury; Upendra K Das
Journal:  Indian J Endocrinol Metab       Date:  2021-09-08

5.  An approach to constitutional delay of growth and puberty.

Authors:  Ashraf T Soliman; Vincenzo De Sanctis
Journal:  Indian J Endocrinol Metab       Date:  2012-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.